Article By:
PropThink
Tuesday, October 21, 2014 12:53 PM EDT
Synergy Pharmaceuticals (SGYP) is getting some much-needed love with phase 2 data, presented at a medical meeting on Monday, for the company's lead drug candidate, plecanatide in Irritable Bowel Syndrome (IBS-C).